nach oben

Erschienen in:

08.12.2023 | Original Communication

Relationship between plasma NFL and disease progression in Parkinson’s disease: a prospective cohort study

verfasst von: Ruwei Ou, Kuncheng Liu, Junyu Lin, Tianmi Yang, Yi Xiao, Qianqian Wei, Yanbing Hou, Chunyu Li, Lingyu Zhang, Zheng Jiang, Bi Zhao, Xueping Chen, Wei Song, Ying Wu, Huifang Shang

Erschienen in: Journal of Neurology | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Objective

We aimed to examine the longitudinal change of plasma neurofilament light chain (NFL) level and explore its diagnostic and prognostic implications in Parkinson’s disease (PD).

Methods

A total of 184 patients with early PD who completed 5-year annually repeated clinical assessments were included. Plasma NFL at baseline, 1 year, and 2 year were examined, which were quantified using the ultrasensitive Simoa technology. At baseline, blood from 86 sex- and age-matched healthy controls (HC) were obtained for comparison.

Results

Plasma NFL in PD patients at baseline was significantly higher than those in HC (P = 0.046), and significantly increased after 2 years (P = 0.046). Receiver operating characteristic curve indicated that a plasma NFL cut-off value of 10.79 pg/mL resulted in 39.7% sensitivity and 84.0% specificity, with an area under the curve of 0.635, to distinguish PD from HC (P < 0.001). Linear mixed-effect models indicated that baseline plasma NFL (> 9.24 pg/mL) correlated with a greater increase in the Unified Parkinson’s Disease Rating Scale III (estimate = 0.651, P = 0.001) and Hoehn & Yahr stage (estimate = 0.072, P < 0.001), and also correlated with a greater decrease in the Montreal Cognitive Assessment (estimate = − 0.387, P < 0.001) during follow-up visits.

Conclusions

Plasma NFL exhibits a tendency to increase with disease progression, and elevated baseline plasma NFL can serve as a predictor for accelerated motor deterioration and cognitive decline in PD. However, plasma NFL does not have high accuracy to distinguish individuals with early-stage PD from HC.

Nur mit Berechtigung zugänglich

Aamodt WW, Waligorska T, Shen J, Tropea TF, Siderowf A, Weintraub D, Grossman M, Irwin D, Wolk DA, Xie SX, Trojanowski JQ, Shaw LM, Chen-Plotkin AS (2021) Neurofilament light chain as a biomarker for cognitive decline in parkinson disease. Mov Disord 36:2945–2950CrossRefPubMedPubMedCentral

Arai H, Schmidt ML, Lee VM, Hurtig HI, Greenberg BD, Adler CH, Trojanowski JQ (1992) Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson’s disease. Neurology 42:1315–1322CrossRefPubMed

Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, Schweighauser M, Eninger T, Lambert M, Pilotto A, Shimshek DR, Neumann U, Kahle PJ, Staufenbiel M, Neumann M, Maetzler W, Kuhle J, Jucker M (2016) Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91:56–66CrossRefPubMed

Backstrom D, Granasen G, Domellof ME, Linder J, Jakobson Mo S, Riklund K, Zetterberg H, Blennow K, Forsgren L (2018) Early predictors of mortality in parkinsonism and Parkinson disease: a population-based study. Neurology 91:e2045–e2056CrossRefPubMedPubMedCentral

Backstrom DC, Eriksson Domellof M, Linder J, Olsson B, Ohrfelt A, Trupp M, Zetterberg H, Blennow K, Forsgren L (2015) Cerebrospinal fluid patterns and the risk of future dementia in early, incident parkinson disease. JAMA Neurol 72:1175–1182CrossRefPubMed

Cochrane CJ, Ebmeier KP (2013) Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis. Neurology 80:857–864CrossRefPubMedPubMedCentral

Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB (2017) Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression. Brain 140:1959–1976CrossRefPubMed

Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S, Toffanin E, Cagnin A, Briani C, Pegoraro E, Soraru G (2017) Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol 74:525–532CrossRefPubMedPubMedCentral

Halliday G, Hely M, Reid W, Morris J (2008) The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol 115:409–415CrossRefPubMed

10.

Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55CrossRefPubMed

11.

Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, Norgren N, Linder J, Forsgren L, Constantinescu R, Zetterberg H, Blennow K, Fs SB (2017) Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88:930–937CrossRefPubMedPubMedCentral

12.

Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442CrossRefPubMed

13.

Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14:577–589CrossRefPubMed

14.

Lin CH, Li CH, Yang KC, Lin FJ, Wu CC, Chieh JJ, Chiu MJ (2019) Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology 93:e1104–e1111CrossRefPubMed

15.

Macleod AD, Taylor KS, Counsell CE (2014) Mortality in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 29:1615–1622CrossRefPubMed

16.

Moberg PJ, Lazarus LW, Mesholam RI, Bilker W, Chuy IL, Neyman I, Markvart V (2001) Comparison of the standard and structured interview guide for the Hamilton depression rating scale in depressed geriatric inpatients. Am J Geriatr Psychiatry 9:35–40CrossRefPubMed

17.

Mollenhauer B, Dakna M, Kruse N, Galasko D, Foroud T, Zetterberg H, Schade S, Gera RG, Wang W, Gao F, Frasier M, Chahine LM, Coffey CS, Singleton AB, Simuni T, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Marek K, Siderowf A, Cedarbaum JM, Hutten SJ, Trenkwalder C, Graham D (2020) Validation of Serum neurofilament light chain as a biomarker of Parkinson’s disease progression. Mov Disord 35:1999–2008CrossRefPubMedPubMedCentral

18.

Movement Disorder Society Task Force on Rating Scales for Parkinson’s D (2003) The Unified Parkinson’s disease rating scale (UPDRS): status and recommendations. Mov Disord 18:738–750CrossRef

19.

Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699CrossRefPubMed

20.

Ng ASL, Tan YJ, Yong ACW, Saffari SE, Lu Z, Ng EY, Ng SYE, Chia NSY, Choi X, Heng D, Neo S, Xu Z, Keong NCH, Tay KY, Au WL, Tan LCS, Tan EK (2020) Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson’s disease. Mol Neurodegener 15:33CrossRefPubMedPubMedCentral

21.

Oosterveld LP, Verberk IMW, Majbour NK, El-Agnaf OM, Weinstein HC, Berendse HW, Teunissen CE, van de Berg WDJ (2020) CSF or serum neurofilament light added to alpha-Synuclein panel discriminates Parkinson’s from controls. Mov Disord 35:288–295CrossRefPubMed

22.

Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P (2019) CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol 18:573–586CrossRefPubMed

23.

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601CrossRefPubMed

24.

Schapira AHV, Chaudhuri KR, Jenner P (2017) Erratum: Non-motor features of Parkinson disease. Nat Rev Neurosci 18:509–509CrossRefPubMed

25.

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653CrossRefPubMed

26.

Weston PSJ, Poole T, Ryan NS, Nair A, Liang Y, Macpherson K, Druyeh R, Malone IB, Ahsan RL, Pemberton H, Klimova J, Mead S, Blennow K, Rossor MN, Schott JM, Zetterberg H, Fox NC (2017) Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology 89:2167–2175CrossRefPubMedPubMedCentral

27.

Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, Barker RA (2013) The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 84:1258–1264CrossRefPubMed

28.

Ye R, Locascio JJ, Goodheart AE, Quan M, Zhang B, Gomperts SN (2021) Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson’s disease: an 8-year longitudinal study. Parkinsonism Relat Disord 85:11–16CrossRefPubMedPubMedCentral

29.

Ygland Rodstrom E, Mattsson-Carlgren N, Janelidze S, Hansson O, Puschmann A (2022) Serum neurofilament light chain as a marker of progression in Parkinson’s disease: long-term observation and implications of clinical subtypes. J Parkinsons Dis 12:571–584CrossRefPubMedPubMedCentral

30.

Zhang L, Cao B, Hou Y, Gu X, Wei Q, Ou R, Zhao B, Luo C, Shang H (2022) Neurofilament light chain predicts disease severity and progression in multiple system atrophy. Mov Disord 37:421–426CrossRefPubMed

Titel: Relationship between plasma NFL and disease progression in Parkinson’s disease: a prospective cohort study
verfasst von: Ruwei Ou
Kuncheng Liu
Junyu Lin
Tianmi Yang
Yi Xiao
Qianqian Wei
Yanbing Hou
Chunyu Li
Lingyu Zhang
Zheng Jiang
Bi Zhao
Xueping Chen
Wei Song
Ying Wu
Huifang Shang
Publikationsdatum: 08.12.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 4/2024
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-12117-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2024

Body mass, neuro-hormonal stress processing, and disease activity in lean to obese people with multiple sclerosis

Frataxin analysis using triple quadrupole mass spectrometry: application to a large heterogeneous clinical cohort

Monoaminergic network dysfunction and development of depression in multiple sclerosis: a longitudinal investigation

Evaluation and management of insomnia in the clinical practice in Italy: a 2023 update from the Insomnia Expert Consensus Group

Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)